Sanofi Considers Counteroffer to J&J's for Actelion

According to a Bloomberg article, Sanofi is discussing a counteroffer for Actelion Ltd., which would challenge Johnson & Johnson's move to acquire the Swiss biotech company, sources said.

Sanofi has informally expressed interest in Actelion, but hasn’t made a final decision on whether to proceed with a bid, the story said.

J&J recently increased its original offer to acquire Actelion, causing potential counter bidders to move quickly.

Read the full story